CD8A and non-small cell lung carcinoma: In patients treated with the immune checkpoint inhibitor pembrolizumab for non-small cell lung cancer, those with a dNLR cutoff < 2.6 had significantly higher objective response rates (ORRs), longer median progression-free survival, and higher numbers of tumor-associated CD8+, FOXP3+, PD-1+ immune cells, and PD-1+ CD8+ T cells [11].